Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer
Stopped early · Phase 2
Conditions studied: Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Other find tumor cells and help kill them or carry tumor-killing substances to them. Giving panitumumab together with paclitaxel and carboplatin may be a better way to block tumor growth. PURPOSE: This phase II trial is studying the side effects and how well paclitaxel and carboplatin together with panitumumab works in treating patients with metastatic triple negative breast cancer.
Key facts
- Study ID
- NCT01009983
- Run by
- Wake Forest University Health Sciences
- People needed
- 14
- Starts
- 2010-03-01
- Expected to finish
- 2013-12-01
- Last updated by the study team
- 2018-07-06
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Ochsner Clinic Foundation — New Orleans, Louisiana, United States
- Wake Forest University Health Sciences — Winston-Salem, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.